Symmetry Medical Inc. Stock Upgraded (SMA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Symmetry Medical (NYSE: SMA) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 4.6%. Since the same quarter one year prior, revenues rose by 20.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 609.3% when compared to the same quarter one year prior, rising from $0.53 million to $3.74 million.
  • SYMMETRY MEDICAL INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SYMMETRY MEDICAL INC reported lower earnings of $0.08 versus $0.40 in the prior year. This year, the market expects an improvement in earnings ($0.58 versus $0.08).
  • SMA's debt-to-equity ratio of 0.72 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Regardless of the somewhat mixed results with the debt-to-equity ratio, the company's quick ratio of 1.18 is sturdy.
  • The gross profit margin for SYMMETRY MEDICAL INC is currently lower than what is desirable, coming in at 28.00%. Regardless of SMA's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, SMA's net profit margin of 3.70% is significantly lower than the same period one year prior.
.

Symmetry Medical Inc. and its subsidiaries designs, develops, and produces implants and related surgical instruments, and cases primarily to orthopedic device manufacturers worldwide. The company has a P/E ratio of 125.2, above the S&P 500 P/E ratio of 17.7. Symmetry Medical has a market cap of $335.5 million and is part of the health care sector and health services industry. Shares are up 6.9% year to date as of the close of trading on Friday.

You can view the full Symmetry Medical Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

5 Stocks Under $10 Set to Soar

4 Stocks Under $10 Making Big Moves

5 Health Care Stocks Under $10 to Watch

Symmetry Medical Inc. Stock Downgraded (SMA)

Symmetry Medical Inc. Stock Upgraded (SMA)